Clinical Trial Update: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Sofosbuvir/velpatasvir fixed-dose combination for 12 weeks vs Sofosbuvir plus ribavirin for 24 weeks in adults with chronic genotype 3 h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-10-26